1. Home
  2. ESEA vs RZLT Comparison

ESEA vs RZLT Comparison

Compare ESEA & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

HOLD

Current Price

$56.55

Market Cap

385.8M

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.30

Market Cap

326.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESEA
RZLT
Founded
2005
2010
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
385.8M
326.4M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
ESEA
RZLT
Price
$56.55
$3.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$62.00
$9.14
AVG Volume (30 Days)
30.5K
4.3M
Earning Date
02-26-2026
02-10-2026
Dividend Yield
4.90%
N/A
EPS Growth
6.77
N/A
EPS
17.38
N/A
Revenue
$223,794,428.00
N/A
Revenue This Year
$10.05
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.29
N/A
Revenue Growth
7.26
N/A
52 Week Low
$26.30
$1.07
52 Week High
$66.00
$11.46

Technical Indicators

Market Signals
Indicator
ESEA
RZLT
Relative Strength Index (RSI) 54.75 48.30
Support Level $53.14 $2.69
Resistance Level $58.55 $3.59
Average True Range (ATR) 1.99 0.27
MACD 0.49 0.24
Stochastic Oscillator 67.22 74.03

Price Performance

Historical Comparison
ESEA
RZLT

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: